Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...
For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...
PDS Biotechnology's HPV-directed immunotherapy is sparking optimism in the biotech industry. Click here to find out why I am ...
Medpage Today on MSN6d
Survival Win for Pembrolizumab in Early Triple-Negative Breast CancerNotably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...
Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...
Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced ...
Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...
Patients with early-stage triple-negative breast cancer tended to have improved survival with neoadjuvant pembrolizumab plus ...
Discover the results from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, presented at ESMO 2024, Barcelona, Spain ...
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced ...
MedPage Today on MSN8d
Another Possible Treatment Option for Intermediate-Stage Liver CancerMedian PFS increased from 10 months with TACE to 14.6 months with the addition of lenvatinib (Lenvima) and pembrolizumab ...
Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery is unknown. In this phase 3 trial, we randomly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback